Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Published:2017-08-03 Issue:6 Volume:117 Page:757-766
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ciuleanu Tudor-Eliade,Ahmed Samreen,Kim Joo-Hang,Mezger Jörg,Park Keunchil,Thomas Michael,Chen Jihong,Poondru Srinivasu,VanTornout Jan M,Whitcomb Debbie,Blackhall Fiona

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017226.pdf

Reference51 articles.

1. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30: 586–623.

2. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR (2010) Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 9: 2652–2664.

3. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O’Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68: 8322–8332.

4. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G SATURN investigators (2010) Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol 11: 521–529.

5. Chung C (2016) Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutations-positive non-small cell lung cancers: an update for recent advances in therapeutics. J Oncol Pharm Pract 22: 461–476.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precise Molecular Subtyping Reveals Heterogeneity of Lung Adenocarcinoma Based on DNA Methylation;Current Medicinal Chemistry;2024-06-05

2. Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development;Biomedicines;2024-03-02

3. IGF-1R targeting in cancer – does sub-cellular localization matter?;Journal of Experimental & Clinical Cancer Research;2023-10-20

4. EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis;International Immunopharmacology;2023-06

5. Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target;Cancers;2023-02-17